Meeting the Analytical Challenges of RNA Therapeutics Development
The rapid growth of RNA therapeutics, including antisense oligonucleotides (ASOs), siRNAs, and mRNA-based drugs, has created new demands for robust analytical tools. During discovery and preclinical development, researchers must evaluate pharmacokinetics (PK), ADME (absorption, distribution, metabolism, and excretion), pharmacodynamics (PD), and immunogenicity to advance the most promising candidates.
Traditional analytical methods such as LC–MS and hybridization-based assays can address many of these parameters, but they often require sequence-specific probes, show reduced sensitivity for longer oligonucleotides, or involve complex workflows and radioactive reagents. These limitations can make oligonucleotide quantification and characterization time-consuming and resource-intensive.
Immunoassay-based approaches offer a powerful alternative. By leveraging high-affinity antibodies against nucleic acids and their modifications, researchers can generate sensitive, sequence-independent data to support RNA therapeutic development. Rockland provides both validated reagents and custom antibody services to help you overcome analytical bottlenecks across diverse RNA modalities.
Why Rockland?
Proven Expertise
Rockland is a trusted partner in RNA therapeutics reserach with decades of experience in developing antibodies to nucleic acid targets.
Innovative Technology
Our ModDetect reagents offer a unique, sequence-independent approach to oligonucleotide detection, enabling sensitive and versatile analysis across RNA modalities
Reproducibility
Validated across multiple platforms and assay formats, our tools deliver consistent, reliable data to support regulatory and research needs